Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.

about

Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.

Item

http://www.wikidata.org/entity/Q47158686

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inherent characteristics of me ...... in the era of targeted agents.

@en

Inherent characteristics of me ...... in the era of targeted agents.

@nl

type

Item

label

Inherent characteristics of me ...... in the era of targeted agents.

@en

Inherent characteristics of me ...... in the era of targeted agents.

@nl

prefLabel

Inherent characteristics of me ...... in the era of targeted agents.

@en

Inherent characteristics of me ...... in the era of targeted agents.

@nl

P1476

Inherent characteristics of me ...... in the era of targeted agents.

@en

P2093

Jang Hee Han

http://www.w3.org/2001/XMLSchema#string

Woong Kyu Han

http://www.w3.org/2001/XMLSchema#string

Young Eun Yoon

http://www.w3.org/2001/XMLSchema#string

P2860

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.

P304

78825-78837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20230

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29108268

http://www.w3.org/2001/XMLSchema#string

P932

5668001

http://www.w3.org/2001/XMLSchema#string